HDAC9 and plasma cell myeloma: Senolytic activity has also been shown for the histone deacetylase (HDAC) inhibitor panobinostat [476] and the dual HDAC/PI3K inhibitor CUDC907 [477] shown to decrease BXL-xL (panobinostat) and Bcl-2 homology domain 3 (CUDC-907), respectively, and that have been applied for treatment of multiple myeloma [478,479].